title: Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.
abstract: Glioblastoma tumors are characterized by their invasiveness and resistance to therapies. The transcription factor signal transducer and activator of transcription 3 (STAT3) was recently identified as a master transcriptional regulator in the mesenchymal subtype of glioblastoma (GBM), which has generated an increased interest in targeting STAT3. We have evaluated more closely the mechanism of action of one particular STAT3 inhibitor, JSI-124 (cucurbitacin I). In this study, we confirmed that JSI-124 inhibits both constitutive and stimulus-induced Janus kinase 2 (JAK2) and STAT3 phosphorylation, and decreases cell proliferation while inducing apoptosis in cultured GBM cells. However, we discovered that before the inhibition of STAT3, JSI-124 activates the nuclear factor-κB (NF-κB) pathway, via NF-κB p65 phosphorylation and nuclear translocation. In addition, JSI-124 treatment induces the expression of IL-6, IL-8, and suppressor of cytokine signaling (SOCS3) mRNA, which leads to a corresponding increase in IL-6, IL-8, and SOCS3 protein expression. Moreover, the NF-κB-driven SOCS3 expression acts as a negative regulator of STAT3, abrogating any subsequent STAT3 activation and provides a mechanism of STAT3 inhibition after JSI-124 treatment. Chromatin immunoprecipitation analysis confirms that NF-κB p65 in addition to other activating cofactors are found at the promoters of IL-6, IL-8, and SOCS3 after JSI-124 treatment. Using pharmacological inhibition of NF-κB and inducible knockdown of NF-κB p65, we found that JSI-124-induced expression of IL-6, IL-8, and SOCS3 was significantly inhibited, showing an NF-κB-dependent mechanism. Our data indicate that although JSI-124 may show potential antitumor effects through inhibition of STAT3, other off-target proinflammatory pathways are activated, emphasizing that more careful and thorough preclinical investigations must be implemented to prevent potential harmful effects.
authors: Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. bdcox@uab.edu
authors: Braden C
authors: BC
authors: McFarland
authors: G Kenneth
authors: GK
authors: Gray
authors: Susan E
authors: SE
authors: Nozell
authors: Suk W
authors: SW
authors: Hong
authors: Etty N
authors: EN
authors: Benveniste
mesh_terms: D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D055785:Gene Knockdown Techniques; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D010766:Phosphorylation; D050796:STAT3 Transcription Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D051996:Transcription Factor RelA / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D014315:Triterpenes / Q000494:pharmacology*
chemical_list: D016328:NF-kappa B; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D051996:Transcription Factor RelA; D014315:Triterpenes; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C038106:cucurbitacin I
references: J Biol Chem. 2004 Jun 18;279(25):26115-25
references: 15073170
references: Nature. 2010 Jan 21;463(7279):318-25
references: 20032975
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: Cancer Cell. 2009 Feb 3;15(2):79-80
references: 19185839
references: Genes Dev. 2006 Nov 1;20(21):2922-36
references: 17079683
references: Neuro Oncol. 2005 Apr;7(2):122-33
references: 15831231
references: J Neurooncol. 2011 May;102(3):367-81
references: 21279667
references: J Biol Chem. 2003 Jun 27;278(26):24233-41
references: 12711606
references: Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62
references: 17183360
references: Nat Rev Immunol. 2007 Jun;7(6):454-65
references: 17525754
references: Cancer Cell. 2009 Dec 8;16(6):487-97
references: 19962667
references: BMC Cancer. 2011 Jun 24;11:268
references: 21702955
references: Genes Dev. 2012 Feb 1;26(3):203-34
references: 22302935
references: J Immunol. 2005 Oct 1;175(7):4338-46
references: 16177074
references: J Immunol. 2010 Aug 15;185(4):2393-404
references: 20631305
references: Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a000141
references: 20066113
references: Genes Dev. 2010 Aug 15;24(16):1731-45
references: 20713517
references: Br J Cancer. 2007 Feb 12;96(3):474-6
references: 17224923
references: Ann N Y Acad Sci. 2009 Aug;1171:59-76
references: 19723038
references: J Immunol. 2010 May 1;184(9):4898-906
references: 20351184
references: Mol Cell Biol. 2008 Nov;28(21):6632-45
references: 18779315
references: J Biol Chem. 2007 Jun 8;282(23):16989-7001
references: 17438332
references: Cancer Cell. 2010 Jan 19;17(1):98-110
references: 20129251
references: Nat Rev Cancer. 2012 Jan 19;12(2):121-32
references: 22257950
references: Nat Rev Cancer. 2005 Apr;5(4):297-309
references: 15803156
references: Nat Rev Cancer. 2009 Nov;9(11):798-809
references: 19851315
references: J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8
references: 17146292
references: Mol Cancer Ther. 2011 Dec;10(12):2384-93
references: 22027691
references: Cancer Res. 2002 Nov 15;62(22):6770-8
references: 12438279
references: Cancer Res. 2003 Mar 15;63(6):1270-9
references: 12649187
references: Cancer Res. 1990 Oct 15;50(20):6683-8
references: 2208133
references: Expert Rev Neurother. 2010 Apr;10(4):575-86
references: 20367209
references: Mol Cell. 2003 Oct;12(4):829-39
references: 14580335
references: Genes Dev. 2011 Dec 15;25(24):2594-609
references: 22190458
references: N Engl J Med. 2008 Jul 31;359(5):492-507
references: 18669428
references: Clin Cancer Res. 2008 Aug 1;14(15):4694-704
references: 18676737
references: J Immunol. 2006 Jul 15;177(2):822-30
references: 16818736
references: J Carcinog. 2010 Jul 14;9:
references: 20808823
references: PLoS Pathog. 2008 Nov;4(11):e1000196
references: 18989459
references: Cancer Biol Ther. 2008 Aug;7(8):1243-9
references: 18487947
references: Mol Cancer Ther. 2010 Dec;9(12):3302-14
references: 21159613
references: J Biol Chem. 2002 Nov 22;277(47):45129-40
references: 12221085
references: Nature. 2008 Oct 23;455(7216):1061-8
references: 18772890
references: N Engl J Med. 2011 Feb 17;364(7):627-37
references: 21175304
references: Immunity. 2012 Apr 20;36(4):542-50
references: 22520847
references: Cancer Cell. 2006 Mar;9(3):157-73
references: 16530701
references: Clin Cancer Res. 2008 Oct 1;14(19):6042-54
references: 18829483
references: J Biol Chem. 1998 Nov 6;273(45):29417-23
references: 9792645
references: J Clin Oncol. 2012 Mar 20;30(9):1005-14
references: 22355058
references: J Biol Chem. 1997 Aug 22;272(34):21096-103
references: 9261113